Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Draft Civil Money Penalty Reduction Policy Needs Clarifications - HIMA

This article was originally published in The Gray Sheet

Executive Summary

FDA's draft policy on civil monetary penalty reductions for small entities is at odds with Sec. 303(f) of the Food Drug & Cosmetic Act because it could be used to exclude certain firms that have violated agency rules within the last five years, the Health Industry Manufacturers Association maintains.
Advertisement

Related Content

FDA Revision Of "Fee Matrix" For Civil Money Penalties Requested By HIMA
FDA Revision Of "Fee Matrix" For Civil Money Penalties Requested By HIMA
"Fee Matrix" Will Determine Device Civil Money Penalties - Draft Guidance
"Fee Matrix" Will Determine Device Civil Money Penalties - Draft Guidance
Advertisement
UsernamePublicRestriction

Register

MT012198

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel